• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

SteadyMed raises another $5m from key shareholder

May 26, 2017 By Sarah Faulkner

SteadyMed TherapeuticsSteadyMed (NSDQ:STDY) said today that 1 of its largest institutional shareholders exercised warrants to purchase additional shares of the company that the investor got in conjunction with the 1st tranche of a previous private placement.

Thanks to the exercise, San Ramon, Calif.-based SteadyMed received an additional $5 million in proceeds.

The company said it is slated to submit a new drug application for its pulmonary arterial hypertension treatment, Trevyent, in the 2nd quarter of this year.

“This additional capital, which follows the successful completion of a $30 million private placement in April, provides us with greater financial resources as we increase our pre-commercial and manufacturing initiatives to support an impactful launch of Trevyent, subject to FDA approval, in mid-2018,” president & CEO Jonathan Rigby said in prepared remarks. “These are exciting times for SteadyMed, and the exercise of these warrants represents an important vote of confidence from one of our largest healthcare-focused institutional investors. We are confident that Trevyent, if approved, will take a meaningful share of the PAH market and our growing body of high quality, diligent investors who support our vision, is a testament to that.”

STDY shares were trading at $7.10 apiece in morning activity today, up 1.4%.

Filed Under: Cardiovascular, Featured, Funding Roundup, Pharmaceuticals, Wall Street Beat Tagged With: SteadyMed Therapeutics

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS